Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-05-06
2008-05-06
Kosar, Andrew D. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S321000
Reexamination Certificate
active
07368426
ABSTRACT:
Methods of treating humans or animals having rheumatoid arthritis are disclosed which include topically administering a therapeutically effective amount of a cyclosporine component to the human or animal, thereby treating the rheumatoid arthritis.
REFERENCES:
patent: 3278447 (1966-10-01), McNicholas
patent: 4388307 (1983-06-01), Cavanak
patent: 4614736 (1986-09-01), Delevallee et al.
patent: 4649047 (1987-03-01), Kaswan
patent: 4814323 (1989-03-01), Andrieu
patent: 4839342 (1989-06-01), Kaswan
patent: 4970076 (1990-11-01), Horrobin
patent: 4990337 (1991-02-01), Kurihara et al.
patent: 4996193 (1991-02-01), Hewitt et al.
patent: 5286730 (1994-02-01), Caufield et al.
patent: 5286731 (1994-02-01), Caufield et al.
patent: 5342625 (1994-08-01), Hauer et al.
patent: 5368854 (1994-11-01), Rennick
patent: 5411952 (1995-05-01), Kaswan
patent: 5474979 (1995-12-01), Ding et al.
patent: 5504068 (1996-04-01), Komiya et al.
patent: 5540931 (1996-07-01), Hewitt et al.
patent: 5719123 (1998-02-01), Morley et al.
patent: 5739105 (1998-04-01), Kim et al.
patent: 5807820 (1998-09-01), Elias
patent: 5843452 (1998-12-01), Wiedmann et al.
patent: 5843891 (1998-12-01), Sherman
patent: 5858401 (1999-01-01), Bhalani et al.
patent: 5866159 (1999-02-01), Hauer et al.
patent: 5891846 (1999-04-01), Ishida et al.
patent: 5916589 (1999-06-01), Hauer et al.
patent: 5951971 (1999-09-01), Kawashima et al.
patent: 5962017 (1999-10-01), Hauer et al.
patent: 5981479 (1999-11-01), Ko et al.
patent: 5981607 (1999-11-01), Ding et al.
patent: 5998365 (1999-12-01), Sherman
patent: 6008191 (1999-12-01), Singh et al.
patent: 6008192 (1999-12-01), Al-Razzak et al.
patent: 6022852 (2000-02-01), Klokkers et al.
patent: 6024978 (2000-02-01), Hauer et al.
patent: 6046163 (2000-04-01), Stuchlik et al.
patent: 6159933 (2000-12-01), Sherman
patent: 6254860 (2001-07-01), Garst
patent: 6323204 (2001-11-01), Burke et al.
patent: 6346511 (2002-02-01), Singh et al.
patent: 6350442 (2002-02-01), Garst
patent: 6413547 (2002-07-01), Bennett et al.
patent: 6420355 (2002-07-01), Richter et al.
patent: 6468968 (2002-10-01), Cavanak et al.
patent: 6486124 (2002-11-01), Olbrich et al.
patent: 2001/0014665 (2001-08-01), Fisher et al.
patent: 2003/0021816 (2003-01-01), Kang et al.
patent: 2003/0044452 (2003-03-01), Ueno
patent: 2003/0055028 (2003-03-01), Stergiopoulos et al.
patent: 2003/0060402 (2003-03-01), Cavanak et al.
patent: 2003/0087813 (2003-05-01), Or et al.
patent: 2003/0104992 (2003-06-01), Or et al.
patent: 2003/0109425 (2003-06-01), Or et al.
patent: 2003/0109426 (2003-06-01), Or et al.
patent: 2003/0143250 (2003-07-01), Hauer et al.
patent: 19810655 (1999-09-01), None
patent: WO 03/030834 (2003-04-01), None
D.E. Yocum, et al. Rheumatology (2000) 39, pp. 156-164.
Acheampong et al, “Cyclosporine Distribution into the Conjunctiva, Cornea, Lacrimal Gland, and Systemic Blood Following Topical Dosing of Cyclosporine to Rabbit, Dog, and Human Eyes,”Lacrimal Gland, Tear Film, and Dry Eye Syndromes 2—Basic Science and Clinical Relevance, Plenum Press, New York & London, © 1998, pp. 1001-1004.
Acheampong et al, “Distribution of Cyclosporin A in Ocular Tissues After Topical Administration to Albino Rabbits and Beagle Dogs,”Curr Eye Res, Feb. 1999, 18(2):91-103b.
Angelov et al, “Preclinical Safety Studies of Cyclosporine Ophthalmic Emulsion,”Lacrimal Gland, Tear Film, and Dry Eye Syndromes 2—Basic Science and Clinical Relevance. Plenum Press. New York & London, © 1998, pp. 991-995.
Brewster et al, “Enhanced Delivery of Ganciclovir to the Brain through the Use of Redox Targeting,”Antimicrobial Agents and Chemotherapy, Apr. 1994, 38(4):817-823.
Brewster et al, “Intravenous and Oral Pharmacokinetic Evaluation of a 2-Hydroxypropyl-∃-cyclodextrin-Based Formulation of Carbamazepine in the Dog: Comparison with Commercially Available Tablets and Suspensions,”J Pharm Sci, Mar. 1997, 86(3):335-9.
Brewster et al, “Preparation, Characterization, and Anesthetic Properties of 2-Hydroxypropyl-∃-cyclodextrin Complexes of Pregnanolone and Pregnenolone in Rat and Mouse,”J Pharm Sci, Oct. 1995. 84(10):1154-9.
Sall et al, “Two Multicenter, Randomized Studies of the Efficacy and Safety of Cyclosporine Ophthalmic Emulsion in Moderate to Severe Dry Eye Disease. CsA Phase 3 Study Group,”Ophthalmology. Apr. 2000. 107(4):631-9.
Small et al, “Blood Concentrations of Cyclosporin A During Long-Term Treatment With Cyclosporin A Ophthalmic Emulsions in Patients With Moderate to Severe Dry Eye Disease,”J Ocul Pharmacol Ther. Oct. 2002, 18(5):411-8.
Stevenson et al., “Efficacy and Safety of Cyclosporin A Ophthalmic Emulsion in the Treatment of Moderate-to-severe Dry Eye Disease,”Ophthalmology, May 2000. 107(5):967-74.
Gaeta G.M. et al: “Cyclosporine bioadhesive gel in the topical treatment of erosive lichen planus”, International Journal of Immunopathology and Pharmacology, vol. 7, No. 2, 1994, pp. 125-132.
T.A. Winter, et al. Scand J Gastroenterol. (1993), 28(8), pp. 701-704.
M. Schwab and U. Klotz, Clin. Pharmacokinet. (2001), 40(10), pp. 723-751.
J. Rudinger. In: Peptide Hormones, JA Parsons, Ed. (1976), pp. 1-7.
D.E. Smilek, et al. Proc. Natl. Acad. Sci. USA (1991) 88, pp. 9633-9637.
MBanić, et al. Dig. Dis. Sci. (2002), 47(6), pp. 1362-1368.
W.J. Sandborn, et al. Am. J. Gastroenterol. (1993), 88(5), pp. 640-645.
D.H. Present. Am. J. Gastroenterol. (1993) 88(5), pp. 627-630.
S. Ardizzone and G.B. Porro. Drugs. (1998), 55(4), pp. 519-542.
W.J. Sandborn, et al. Gastroenterology. (1994), 106(6), pp. 1429-1435.
A.A. Drosos, et al. Scand. J. Rheumatology (1986) Suppl. 61, pp. 246-249.
W.A. van der Reijden, et al. Ann. Rheum. Dis. (1999), 58, pp. 465-473.
N.A. Robinson and D. Wray. Australian Dental Journal (2003), 48(4), pp. 206-211.
A.M. Pedersen and B. Nauntofte. Expert Opin. Pharmacother. (2001), 2(9), pp. 1415-1436.
Gunduz et al, “Topical Cyclosporin Treatment of Keratoconjunctivitis Sicca in Secondary Sjogren's Syndrome”, Acta Ophthalmologica, vol. 72, No. 4, 1994, pp. 438-442, XP009063039.
Phillips et al, “Cyclosporine Has A Direct Effect on the Differentiation of a Mucin-Secreting Cell Line”, Journal of Cellular Physiology, vol. 184, No. 3, Sep. 2000, pp. 400-408, XP009063023.
Gipson et al, “Character of Ocular Surface Mucins and Their Alteration in Dry Eye Disease”, The Ocular Surface, vol. 2, No. 2, Apr. 2004, pp. 131-148, XP001208377.
Akpek et al, “A Randomized Trial of Topical Cyclosporin 0.05% in Topical Steroid-Resistant Atopic Keratoconjunctivitis”, Ophthalmology, vol. III, No. 3, Mar. 2004, pp. 476-482, XP009063021.
Eisen et al. “Topical Cyclosporine for Oral Mucosal Disorders”, Journal of the American Academy of Dermatology, vol. 23, No. 6, Part 2, Dec. 1990, pp. 1259-1264, XP009063043.
Epstein et al, “Topical Cyclosporine in a Bioadhesive for Treatment of Oral Lichenoid Mucosal Reactions. An Open Label Clinical Trial”, Oral Surgery, Oral Medicine . . . , vol. 82, No. 5, 1996, pp. 532-536, XP009063045.
Erdmann et al, “Pemphigus Vulgaris Der Mund-Und Kehlopfschleimhaut Pemphigus Vulgaris of the Oral Mucosa and the Larynx”, H+G Zeitschrift Fuer Hautkrankheiten, vol. 72. No. 4, 1997, pp. 283-296, XP009063042.
Brinkmeier et al. “Pyodermatitis-Pyostomatitis Vegetans: A Clinical Course of Two Decades with Response to Cyclosporine and Low-Dose Prednisolone”, Acta Dermato-Venereologica, vol. 81, No. 2, May 2001, pp. 134-136.
Gremse et al, “Ulcerative Colitis in Children. Medical Management”, Pediatric Drugs, vol. 4, No. 12, 2002, pp. 807-815, XP009063025.
The Online Medical Dictionary, http://cancerweb.ncl.ac.uk/omd/about.html, accessed Jul. 7, 2005 and Jul. 13, 2005, 6 pages. Four (4) definitions accessed from the On-line Medical Dictionary: derivative; analog; analogue and xerostomia.
K. Tsubota, et al., “Use of Topical Cyclosporin A in a Pr
Power David
Stern Michael E.
Allergan Inc.
Kosar Andrew D.
Stout, Uxa Buyan & Mullins, LLP
Uxa Frank J.
LandOfFree
Methods for the therapeutic use of cyclosporine components does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for the therapeutic use of cyclosporine components, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for the therapeutic use of cyclosporine components will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2799134